Guardant Health, Inc. (GH) Financials
Annual revenue, profitability and per-share results for Guardant Health, Inc., as reported in SEC filings.
Revenue • FY2025
$982.02M
▲ 32.9%YoY
Net income • FY2025
-$416.28M
▲ 4.6%YoY
Gross margin • FY2025
64.5%
Diluted EPS • FY2025
$-3.32
▲ 6.7%YoY
Annual income statement
| Period | Revenue | Net income | Gross profit | Dil. EPS | Free cash flow | Op. margin | Rev. growth |
|---|---|---|---|---|---|---|---|
| FY2025 | $982.02M | -$416.28M | $633.01M | $-3.32 | -$233.07M | -44.5% | +32.9% |
| FY2024 | $739.02M | -$436.37M | — | $-3.56 | -$274.94M | -60.0% | +31.0% |
| FY2023 | $563.95M | -$479.45M | — | $-4.28 | -$345.46M | -100.1% | +25.4% |
| FY2022 | $449.54M | -$654.59M | — | $-6.41 | -$386.92M | -121.1% | +20.3% |
Figures as reported in Guardant Health, Inc.'s 10-K filings on SEC EDGAR. Fiscal years may differ from calendar years.
Never miss a GH filing.
Get an email when GH files its next 8-K, Form 4, 10-K or 10-Q with the SEC. Free, no account needed.
Free foreverNo account requiredOne-click unsubscribe
Source: SEC EDGAR.